Dysregulation of glutamate carboxypeptidase II in psychiatric disease

Schizophrenia Research

Volumn 99, Issue 1-3, 2008, Pages 324-332

  Guilarte, Tomás R ^a   Hammoud, Dima A ^b   McGlothan, Jennifer L ^a   Caffo, Brian S ^a   Foss, Catherine A ^b   Kozikowski, Alan P ^c   Pomper, Martin G ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

125I DCIT; Bipolar disorder; Depression; GCPII; Human brain; Imaging; NAALADase; Schizophrenia

Indexed keywords

GLUTAMATE CARBOXYPEPTIDASE II; IODINE 125; N [N (1,3 DICARBOXYPROPYL)CARBAMOYL] S 3 IODO LEVO TYROSINE I 125; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTORADIOGRAPHY; BIPOLAR DISORDER; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; FEMALE; HUMAN; HUMAN TISSUE; MALE; MENTAL DISEASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCHIZOPHRENIA;

ADULT; AGED; AUTORADIOGRAPHY; BIPOLAR DISORDER; CARBAMATES; DEPRESSIVE DISORDER; DOMINANCE, CEREBRAL; ENTORHINAL CORTEX; FEMALE; GLUTAMATE CARBOXYPEPTIDASE II; HIPPOCAMPUS; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PREFRONTAL CORTEX; REFERENCE VALUES; SCHIZOPHRENIA; TEMPORAL LOBE; TYROSINE;

EID: 39149139643     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.11.013     Document Type: Article

References (47)

1. Abelli M., Martini C., Pini S., Gesi C., and Cassano G.B. The role of newer antiglutamatergic agents as mood-stabilizers in bipolar disorder. Curr. Drug Targets 6 (2005) 607-614
2. Belsham B. Glutamate and its role in psychiatric illness. Hum. Psychopharmacol. 16 (2001) 139-146
3. Beneyto, M., Kristiansen, L.V., Oni-Orisan, A., McCullumsmith, R.E., Meador-Woodruff, J.H., in press. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology (Electronic Publication ahead of print).
4. Bergeron R., Coyle J.T., Tsai G., and Greene R.W. NAAG reduces NMDA receptor current in CA1 hippocampal pyramidal neurons of acute slices and dissociated neurons. Neuropsychopharmacology 30 (2005) 7-16
5. Bergeron R., Imamura Y., Frangioni J.V., Greene R.W., and Coyle J.T. Endogenous N-acetylaspartylglutamate reduced NMDA receptor-dependent current neurotransmission in the CA1 area of the hippocampus. J. Neurochem. 100 (2007) 346-357
6. Bertolino A., Nawroz S., Mattay V.S., Barnett A.S., Duyn J.H., Moonen C.T., et al. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am. J. Psychiatry 153 (1996) 1554-1563
7. Blakely R.D., Robinson M.B., Thompson R.C., and Coyle J.T. Hydrolysis of the brain dipeptide N-acetyl-l-aspartyl-l-glutamate: subcellular and regional distribution, ontogeny, and the effect of lesions on N-acetylated-alpha-linked acidic dipeptidase activity. J. Neurochem. 50 (1988) 1200-1209
8. Callicott J.H., Bertolino A., Mattay V.S., Langheim F.J., Duyn J., Coppola R., et al. Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb. Cortex 10 (2000) 1078-1092
9. Choudary P.V., Molnar M., Evans S.J., Tomita H., Li J.Z., Vawter M.P., et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 15653-15658
10. Clapcote S.J., Lipina T.V., Millar J.K., Mackie S., Christie S., Ogawa F., et al. Behavioral phenotypes of Disc1 missense mutations in mice. Neuron 54 (2007) 387-402
11. Coyle J.T. The GABA-glutamate connection in schizophrenia: which is the proximate cause?. Biochem. Pharmacol. 68 (2004) 1507-1514
12. Coyle J.T. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell. Mol. Neurobiol. 26 (2006) 365-384
13. Delamillieure P., Constans J.M., Fernandez J., Brazo P., Benali K., Courtheoux P., et al. Proton magnetic resonance spectroscopy (1H MRS) in schizophrenia: investigation of the right and left hippocampus, thalamus, and prefrontal cortex. Schizophr. Bull. 28 (2002) 329-339
14. Duvernoy H.M., and Bourgouin P. The human hippocampus: functional anatomy, vascularization and serial sections with MRI (1998), Springer-Verlag, New York, NY
15. Foss C.A., Mease R.C., Fan H., Wang Y., Ravert H.T., Dannals R.F., et al. Radiolabeled small molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin. Cancer Res. 11 (2005) 4022-4028
16. Ghose S., Weickert C.S., Colvin S.M., Coyle J.T., Herman M.M., Hyde T.M., et al. Glutamate carboxypeptidase II gene expression in the human frontal and temporal lobe in schizophrenia. Neuropsychopharmacology 29 (2004) 117-125
17. 125I]DCIT quantitative autoradiography. Neurosci. Lett. 387 (2005) 141-144
18. Hakak Y., Walker J.R., Li C., Wong W.H., Davis K.L., Buxbaum J.D., et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 4746-4751
19. Harrison P.J. The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. Psychopharmacology (Berl) 174 (2004) 151-162
20. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148 (1991) 1301-1308
21. Kim J.S., Kornhuber H.H., Schmid-Burgk W., and Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 20 (1980) 379-382
22. Lambert L.A., and Mitchell S.L. Molecular evolution of the transferrin receptor/glutamate carboxypeptidase II family. J. Mol. Evol. 64 (2007) 113-128
23. Laruelle M., Frankle W.G., Narendran R., Kegeles L.S., and Abi-Dargham A. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation. Clin. Ther. 27 Suppl A (2005) S16-S24
24. Lea P.M.T., Wroblewska B., Sarvey J.M., and Neale J.H. beta-NAAG rescues LTP from blockade by NAAG in rat dentate gyrus via the type 3 metabotropic glutamate receptor. J. Neurophysiol. 85 (2001) 1097-1106
25. Lewis D.A., and Gonzalez-Burgos G. Pathophysiologically based treatment interventions in schizophrenia. Nat. Med. 12 (2006) 1016-1022
26. Lim K.O., Adalsteinsson E., Spielman D., Sullivan E.V., Rosenbloom M.J., and Pfefferbaum A. Proton magnetic resonance spectroscopic imaging of cortical gray and white matter in schizophrenia. Arch. Gen. Psychiatry 55 (1998) 346-352
27. Losi G., Vicini S., and Neale J. NAAG fails to antagonize synaptic and extrasynaptic NMDA receptors in cerebellar granule neurons. Neuropharmacology 46 (2004) 490-496
28. Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., and Kelley R. Study of a new schizophrenomimetic drug; sernyl. AMA. Arch. Neurol. Psychiatry 81 (1959) 363-369
29. Luthi-Carter R., Barczak A.K., Speno H., and Coyle J.T. Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase). J. Pharmacol. Exp. Ther. 286 (1998) 1020-1025
30. Maier M., Ron M.A., Barker G.J., and Tofts P.S. Proton magnetic resonance spectroscopy: an in vivo method of estimating hippocampal neuronal depletion in schizophrenia. Psychol. Med. 25 (1995) 1201-1209
31. Molina V., Sanz J., Sarramea F., Luque R., Benito C., and Palomo T. No association between dorsolateral prefrontal gray matter deficit and N-acetyl aspartate ratios in schizophrenia. Neuropsychobiology 54 (2006) 171-178
32. Neale J.H., Olszewski R.T., Gehl L.M., Wroblewska B., and Bzdega T. The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia. Trends Pharmacol. Sci. 26 (2005) 477-484
33. Nudmamud S., Reynolds L.M., and Reynolds G.P. N-acetylaspartate and N-acetylaspartylglutamate deficits in superior temporal cortex in schizophrenia and bipolar disorder: a postmortem study. Biol. Psychiatry 53 (2003) 1138-1141
34. Ohnuma T., Suzuki T., and Arai H. Hypothesis: minimal changes in neural transmission in schizophrenia: decreased glutamatergic and GABAergic functions in the prefrontal cortex. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 29 (2005) 889-894
35. Olney J.W., Newcomer J.W., and Farber N.B. NMDA receptor hypofunction model of schizophrenia. J. Psychiatr. Res. 33 (1999) 523-533
36. Olszewski R.T., Bukhari N., Zhou J., Kozikowski A.P., Wroblewski J.T., Shamimi-Noori S., et al. NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. J. Neurochem. 89 (2004) 876-885
37. Pomper M.G., Musachio J.L., Zhang J., Scheffel U., Zhou Y., Hilton J., et al. 11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Mol. Imaging 1 (2002) 96-101
38. Riveros N., and Orrego F. A study of possible excitatory effects of N-acetylaspartylglutamate in different in vivo and in vitro brain preparations. Brain. Res. 299 (1984) 393-395
39. Sacha P., Zamecnik J., Barinka C., Hlouchova K., Vicha A., Mlcochova P., et al. Expression of glutamate carboxypeptidase II in human brain. Neuroscience 144 (2006) 1361-1372
40. Stanley J.A., Vemulapalli M., Nutche J., Montrose D.M., Sweeney J.A., Pettegrew J.W., et al. Reduced N-acetyl-aspartate levels in schizophrenia patients with a younger onset age: a single-voxel (1)H spectroscopy study. Schizophr. Res. 93 (2007) 23-32
41. Torrey E.F., Webster M., Knable M., Johnston N., and Yolken R.H. The stanley foundation brain collection and neuropathology consortium. Schizophr. Res. 44 (2000) 151-155
42. Tsai S.J. Central N-acetyl aspartylglutamate deficit: a possible pathogenesis of schizophrenia. Med. Sci. Monit. 11 (2005) HY39-HY45
43. Tsai G., Passani L.A., Slusher B.S., Carter R., Baer L., Kleinman J.E., et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch. Gen. Psychiatry 52 (1995) 829-836
44. Urazaev A.K., Grossfeld R.M., and Lieberman E.M. Regulation of glutamate carboxypeptidase II hydrolysis of N-acetylaspartylglutamate (NAAG) in crayfish nervous tissue is mediated by glial glutamate and acetylcholine receptors. J. Neurochem. 93 (2005) 605-610
45. Webster M.J. Tissue preparation and banking. Prog. Brain. Res. 158 (2006) 3-14
46. Weinberger D.R. Genetic mechanisms of psychosis: in vivo and postmortem genomics. Clin. Ther. 27 Suppl A (2005) S8-S15
47. Zhou J., Neale J.H., Pomper M.G., and Kozikowski A.P. NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat. Rev. Drug. Discov. 4 (2005) 1015-1026